Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-01

Esperion Therapeutics, Inc. (ESPR)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$3,535,512
Sheldon Koenig total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
73.29%
Say-on-pay support, latest vote
Companies that benchmark against ESPR
8 companies name ESPR as a compensation peer

Each company listed discloses ESPR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ESPR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Sheldon Koenig$770,833$0$1,260,000$847,929$639,375$0$17,375$3,535,512
President and Chief Executive Officer
John Harlow66,87535,0001,608,9911,101,468007692,813,103
Chief Commercial Officer
Benjamin Halladay495,8330357,000239,852247,500011,7501,351,935
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Sheldon Koenig$3,535,512$3,175,240+360,272
John Harlow2,813,103
Benjamin Halladay1,351,935

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

No insider equity transactions reported since the proxy statement.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
John HarlowOTHER$1,608,991
Sheldon KoenigOPTION847,929
Benjamin HalladayOTHER357,000
John HarlowOPTION1,101,468
Benjamin HalladayOPTION239,852
Sheldon KoenigOTHER1,260,000
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
John Harlow$0$0$1,101,4680.0%
Sheldon Koenig00847,9290.0%
Benjamin Halladay00239,8520.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Benjamin HalladayRSU193,375$715,488
Sheldon KoenigRSU7,25026,825
Sheldon KoenigOption611,8141.5
Sheldon KoenigRSU682,5002,525,250
Sheldon KoenigRSU255,375944,888
Benjamin HalladayRSU95,625353,813
Benjamin HalladayRSU11,00040,700
John HarlowRSU424,5361,570,783
Sheldon KoenigOption361,1252.05
Benjamin HalladayRSU2,87510,638
Benjamin HalladayOption16,5005.09
Benjamin HalladayRSU4001,480
Benjamin HalladayOption12,1934.02
John HarlowOption380,0003.79
Sheldon KoenigOption139,0684.02
Benjamin HalladayOption173,0641.5
Benjamin HalladayOption112,5002.05
Sheldon KoenigRSU32,818121,427
Sheldon KoenigOption30,7504.74
05

Incentive-plan design — the Compensation Discussion & Analysis

we have developed a compensation program that is designed to attract and retain key executives responsible for our success and motivate management to enhance long-term stockholder value. The executive compensation program is designed to reward short-term and long-term performance and to align the financial interests of our executive officers with the interests of our stockholders.

CEO STI target (% of salary)75%
CEO LTI target (% of salary)
Independent consultant
Clawback policyTrue
Anti-hedgingtrue
Anti-pledgingfalse
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2895,650,22634,866,033577,79573.29%Passed
20252025-05-2970,756,44026,653,5781,483,17672.64%Passed
20242024-05-2370,745,16424,537,427439,90374.25%Passed
20232023-06-1537,435,09614,031,443197,71572.74%Passed
20212021-05-2715,003,3621,102,322121,02693.16%Passed
20202020-05-2815,375,523476,00148,33297%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2873.29%a
20252025-05-2972.64%b
20242024-05-2374.25%c

a. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will have no effect on such proposals.”.

b. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will have no effect on such proposals.”.

c. Approved under the standard stated in the filing — “Abstentions and "broker non-votes" will have no effect on such proposals.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
J. Martin CarrollIndependent · Board Chair · Audit · Compliance (Chair)$95,000$28,730$28,474$0$152,204
Seth H.Z. FischerIndependent · Compensation (Chair) · Commercial · Compliance75,50428,73028,4740132,708
Tracy M. WoodyIndependent · Nominating/Governance · Commercial (Chair) · Not standing for re-election72,25856,9480129,206
Jay P. ShepardIndependent · Nominating/Governance (Chair) · Commercial70,50428,73028,4740127,708
Stephen RocamboliIndependent · Audit · Compensation · Not standing for re-election67,50028,73028,4740124,704
Robert E. HoffmanIndependent · Audit (Chair) · Compensation · Newly elected35,2624,59746,519086,378
Nicole VitulloIndependent · Departed during FY45,18832,917078,105
Antonio M. Gotto, Jr., M.D., D.PhilIndependent · Departed during FY36,819030,00066,819
Alan FuhrmanIndependent · Compensation · Departed during FY51,250051,250
Craig ThompsonIndependent · Nominating/Governance · Commercial · Compliance · Newly elected17,50029,999047,499
Sheldon L. KoenigEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$35,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$566,785
Equity awards (grant-date value)$119,517
All other compensation$30,000
Total cost of the board$716,302

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Esperion Therapeutics, Inc.2025Sheldon Koenig$770,833$1,260,000$847,929$639,375$3,535,512

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

FAQ

Frequently asked questions

Who was the highest-paid executive at Esperion Therapeutics, Inc. in fiscal 2025?
Sheldon Koenig was the highest-paid executive at Esperion Therapeutics, Inc. in fiscal 2025, with total compensation of $3,535,512.
How does Esperion Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
The CEO pay percentile of disclosed peers is not disclosed in this extract.
What is Esperion Therapeutics, Inc.'s CEO-to-median employee pay ratio?
The CEO-to-median employee pay ratio is not disclosed in this extract.
How did shareholders vote on Esperion Therapeutics, Inc.'s executive compensation?
Shareholders supported the executive compensation plan with 73.29% approval in the latest vote.
How much does Esperion Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
Esperion Therapeutics, Inc. spent $716,302 in total board compensation for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Sheldon KoenigDEF 14A2026-04-160001628280-26-025499Section “2025 Summary Compensation Table”. As printed: 3,535,512. Filing ↗machine: span 423838–423847
2Section 01, John HarlowDEF 14A2026-04-160001628280-26-025499Section “2025 Summary Compensation Table”. As printed: 2,813,103. Filing ↗machine: span 439574–439583
3Section 01, Benjamin HalladayDEF 14A2026-04-160001628280-26-025499Section “2025 Summary Compensation Table”. As printed: 1,351,935. Filing ↗machine: span 431667–431676
4Section 03, John Harlow OTHERDEF 14A2026-04-160001628280-26-025499Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r8 · c8 · span 437733–437742
5Section 03, Sheldon Koenig OPTIONDEF 14A2026-04-160001628280-26-025499Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r3 · c11 · span 422368–422375
6Section 03, Benjamin Halladay OTHERDEF 14A2026-04-160001628280-26-025499Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r6 · c9 · span 430174–430181
7Section 03, John Harlow OPTIONDEF 14A2026-04-160001628280-26-025499Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r8 · c10 · span 438093–438102
8Section 03, Benjamin Halladay OPTIONDEF 14A2026-04-160001628280-26-025499Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r6 · c11 · span 430482–430489
9Section 03, Sheldon Koenig OTHERDEF 14A2026-04-160001628280-26-025499Section “EXECUTIVE OFFICER AND DIRECTOR COMPENSATION” · grants of plan-based awards table. Filing ↗machine: t18 · r3 · c9 · span 421956–421965
10Section 07, pay ratio10-K2026-03-100001628280-26-016522Section “CEO Pay Ratio”. As printed: —. Filing ↗
11Section 08, J. Martin CarrollDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 152,204. Filing ↗machine: t23 · r3 · c10 · span 668041–668048
12Section 08, Seth H.Z. FischerDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 132,708. Filing ↗machine: t23 · r4 · c10 · span 670222–670229
13Section 08, Tracy M. WoodyDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 129,206. Filing ↗machine: t23 · r12 · c10 · span 689703–689710
14Section 08, Jay P. ShepardDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 127,708. Filing ↗machine: t23 · r9 · c10 · span 682533–682540
15Section 08, Stephen RocamboliDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 124,704. Filing ↗machine: t23 · r8 · c10 · span 680294–680301
16Section 08, Robert E. HoffmanDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 86,378. Filing ↗machine: t23 · r7 · c10 · span 677616–677622
17Section 08, Nicole VitulloDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 78,105. Filing ↗machine: t23 · r11 · c10 · span 687532–687538
18Section 08, Antonio M. Gotto, Jr., M.D., D.PhilDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 66,819. Filing ↗machine: t23 · r6 · c10 · span 675044–675050
19Section 08, Alan FuhrmanDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 51,250. Filing ↗machine: t23 · r5 · c2 · span 671281–671287
20Section 08, Craig ThompsonDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 47,499. Filing ↗machine: t23 · r10 · c10 · span 685141–685147
21Section 08, Sheldon L. KoenigDEF 14A2026-04-160001628280-26-025499Section “Director Compensation”. As printed: 0. Filing ↗
22Section 06, 2026 voteForm 8-K2026-06-010001628280-26-039518Item 5.07 · say-on-pay result. As reported: 73.29% (votes for as printed: 95,650,226). Filing ↗
23Section 06, 2025 voteForm 8-K2025-06-020001628280-25-028820Item 5.07 · say-on-pay result. As reported: 72.64% (votes for as printed: 70,756,440). Filing ↗
24Section 06, 2024 voteForm 8-K2024-05-280001628280-24-025418Item 5.07 · say-on-pay result. As reported: 74.25% (votes for as printed: 70,745,164). Filing ↗
25Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
26Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
27Section 09b board cost (computed)ComputedcomputedCash 566,785 + equity 119,517 + all other 30,000 = 716,302, summed across the director compensation table rows.machine: formula: Σ = 716,302
28Esperion Therapeutics, Inc. (subject), Section 10b CEO totalDEF 14A2026-04-160001628280-26-025499CEO total compensation as printed in Esperion Therapeutics, Inc.'s own proxy. As printed: 3,535,512. Filing ↗machine: span 423838–423847